Alongside other prominent Bay Area medical centers like St. Mary’s SF and Stanford Medical Center, Contra Costa Oncology is now offering IMLYGIC for local treatment of melanoma that is recurrent after initial surgery. Contra Costa Oncology is currently the only medical center in the East Bay patients can receive this therapy.
Please speak with your physician to see if IMLYGIC is a fit for you.
About IMLYGIC® (talimogene laherparepvec)
IMLYGIC® (talimogene laherparepvec) is a genetically modified herpes simplex type 1 virus that is injected directly into tumors. IMLYGIC replicates inside tumor cells and produces GM-CSF, an immunostimulatory protein. IMLYGIC then causes the cell to rupture and die in a process called lysis. The rupture of the cancer cells causes the release of tumor-derived antigens, which together with virally derived GM-CSF may help to promote an anti-tumor immune response. However, the exact mechanism of action is unknown.
IMLYGIC is the first oncolytic viral therapy approved by the U.S. Food and Drug Administration (FDA) based on therapeutic benefit demonstrated in a pivotal study. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC has not been shown to improve OS or have an effect on visceral metastases.
For additional information, please speak with your physician and visit the IMLYGIC website.